



AF

1625  
TEW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit 1625

In re

Patent Application of

Charles Raymond Degenhardt

Application No. 09/996,657

Confirmation No.: 6277

Filed: November 29, 2001

Examiner: Rita J. Desai

“SUBSTITUTED HETEROCYCLIC  
COMPOUNDS FOR TREATING  
MULTIDRUG RESISTANCE”

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97(c) and (e)(2)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Anna Poppe, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Anna Poppe  
Signature


November 17, 2005  
Date of Signature

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08B and copies of non-U.S. patent references are attached. Citation of these references is respectfully requested.

In accordance with 37 CFR 1.97(c) and (e)(2), the undersigned hereby certifies that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,

  
Wendy M. Seffrood  
Reg. No. 52,205

File No. 010785-9003-02

Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
608.257.3501

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/996,657	
			Filing Date	November 29, 2001	
			First Named Inventor	Charles Raymond Degenhardt	
			Group Art Unit	1625	
			Examiner Name	Rita J. Desai	
Sheet	1	of	1	Attorney Docket Number	010785-9003-02

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		BATES et al., "New ABC transporters in multi-drug resistance," Emerging Therapeutic Targets (2000) 4(5): 561-580
		BATES et al., "A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma," Clinical Cancer Research (2004) 10:4724-4733
		CHIBA et al., "Inhibitors of ABC-type drug efflux pumps: an overview of the current patent situation," Expert Opinion (2004) 14(4):499-508
		DE MILITO et al., "Proton pump inhibitors may reduce tumour resistance," Expert Opinion Pharmacother. (2005) 6(7): 1049-1054
		PUSZTAI, L. et al., "Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistance, advanced breast carcinoma," Amer. Cancer Soc. (2005) 682-691
		THOMAS, H. et al., "Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein," Cancer Control (2003) 10(2):159-165

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.